Sangamo BioSciences | SGMO - Current Assets


Sangamo BioSciences reported $49.89M in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amgen USD 31.48B 2.42B Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Grifols EUR 5.96B 316.31M Dec/2025
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pfizer USD 42.82B 76M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026